Prospective Evidence Links Textured Breast Implants to Rare Lymphoma
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
Diagnosis & Disease Information
Breastfeeding Duration May Influence Markers of Inflammation and Proliferation in Breast Tissue of Healthy Parous Women
Morphologic features were examined to identify markers of inflammation, and proliferation index was assessed using Ki67 immunostaining.
Efficacy of Maintenance Therapy After Induction Therapy in Patients With Nonsquamous NSCLC and Wild-Type EGFR
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy Versus Gefitinib Alone
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.
RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC
RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCC
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Early MRD Status After CAR-T Administration Predicted PFS, OS
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
Adding Apalutamide to ADT Prolongs Survival in mCSPC
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
Earlier Pembrolizumab Use May Be Beneficial in mUC
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
- Loading...
Loading...
Next post in Bladder Cancer
Loading... 
Loading...